Tyra Biosciences, Inc.
NASDAQ:TYRABiotechnology
-$0.72 today
- Market cap
- $1.35B
- Beta
- 0.75
- P/E (TTM)
- -13.4
- EPS (TTM)
- -$2.12
Volume 0.47M
Average 0.96M
TYRA Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Tyra Biosciences, Inc.NASDAQ: TYRA
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents falls 15.7% from a year ago
Cash & equivalents stood at $84.96M at the end of Q1 FY2026, down 15.7% from a year earlier and up 9.8% from the prior quarter. Over 3 fiscal years it compounded at -32.5% a year.
Context
- Cash & equivalents amounted to 20.6% of total assets at the end of Q1 FY2026, down 8.7 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -15.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 77.39M USD
- Year-over-year change
- -15.9%
- 4-year CAGR
- -28.9%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 77.39M | -15.9% |
| FY2024 | 2024-12-31 | 91.97M | +58.5% |
| FY2023 | 2023-12-31 | 58.01M | -76.9% |
| FY2022 | 2022-12-31 | 251.21M | -16.9% |
| FY2021 | 2021-12-31 | 302.18M | — |
Cash & Equivalents vs competitors
How TYRA compares with its peers on the latest reported figures
- TYRA's Mar 2026 cash & equivalents of $84.96M is the 5th highest of the 11 companies compared; the peer median is $70.8M.
- Its year-over-year change of -15.7% is the 7th highest of 11, against a peer median of +1.1%.
- Cash & equivalents amounts to 20.6% of total assets for TYRA, versus a peer median of 24.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
BCAXBicara Therapeutics Inc. Common Stock | Mar 2026 | $323.46M | -30.0% | +185.4% | 58.4% |
| Jun 2026 | $258.6M | +4.3% | +17.5% | 34.7% | |
| Mar 2026 | $165.55M | +40.8% | +39.9% | 72.7% | |
| Mar 2026 | $88.91M | +45.7% | +15.7% | 40.0% | |
| Mar 2026 | $84.96M | -15.7% | -32.5% | 20.6% | |
| Mar 2026 | $75.08M | -2.1% | -17.3% | 18.6% | |
| Mar 2026 | $66.52M | -54.3% | -19.3% | 30.5% | |
| Mar 2026 | $62.1M | +24.5% | -34.7% | 17.8% | |
| Mar 2026 | $56.4M | +14.3% | -11.9% | 12.9% | |
| Mar 2026 | $51.83M | -29.7% | +0.6% | 5.0% | |
| Mar 2026 | $39.08M | -23.8% | +42.2% | 6.0% | |
| Peer median (excluding TYRA) | $70.8M | +1.1% | +8.1% | 24.6% | |
Competitors are the stored peer set for TYRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 302.18M | 251.21M | 58.01M | 91.97M | 77.39M |
| Short-term Investments | 0 | 0 | 145.46M | 249.48M | 178.62M |
| Net Receivables | 0 | 0 | 0 | 2M | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 6.08M | 8.2M | 4.02M | 9.45M |
| Total Current Assets | 304.06M | 257.29M | 211.67M | 347.46M | 265.45M |
| Property, Plant & Equipment (Net) | 2.09M | 3.54M | 8.15M | 7.72M | 6.89M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 555K | 5.35M | 6.03M | 8.38M | 10.27M |
| Total Non-current Assets | 2.64M | 8.89M | 14.19M | 16.1M | 17.16M |
| Total Assets | 306.7M | 266.18M | 225.86M | 363.56M | 282.61M |
| Account Payables | 599K | 1.15M | 4.66M | 590K | 1.18M |
| Short-term Debt | 0 | 0 | 0 | 412K | 472K |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 5.27M | 7.14M | 10.91M |
| Total Current Liabilities | 3.62M | 5.7M | 15.33M | 14.59M | 18.09M |
| Long-term Debt | 0 | 0 | 0 | 0 | 5.34M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 367K | 169K | 46K | 3K | 0 |
| Total Non-current Liabilities | 1.35M | 2.65M | 6.26M | 5.81M | 5.34M |
| Total Liabilities | 4.96M | 8.35M | 21.6M | 20.41M | 23.43M |
| Common Stock | 4K | 4K | 4K | 5K | 5K |
| Retained Earnings | (40.37M) | (95.7M) | (164.83M) | (251.31M) | (371.26M) |
| Accumulated OCI | 0 | 0 | 381K | 770K | 393K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 301.74M | 257.83M | 204.26M | 343.15M | 259.18M |
| Total Debt | 1.18M | 2.62M | 6.5M | 6.22M | 5.81M |
| Net Debt | (301M) | (248.59M) | (51.51M) | (85.74M) | (71.58M) |
Tyra Biosciences, Inc.
NASDAQ:TYRA
Intrinsic Alpha fair value
Locked
Current Price
$19.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.